RegCell venture announces study on iPS treatment for rheumatoid arthritis

RegCell Co. is a spin-out of Osaka University’s Immunological Frontier Research Center (IFReC), supported by iPS portal, Kyoto City. The company will attempt to apply autologous regulatory T cells for the treatment of rheumatoid arthritis.

https://regcell.jp

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny